🇺🇸 UroGen Pharma Ltd.
Forum topic · URGN · Company page: financials, ownership and filings
Join the discussion on UroGen Pharma Ltd.
Loading…
Results announced on 4 November 2026
UroGen Pharma Ltd. announced results on 4 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $89 million (up 224% from a year earlier) and a net loss of $1 million.
Insider trading in October 2026
Directors and officers of UroGen Pharma Ltd. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $80,791 in 1 trade.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 107 funds hold $211 million
107 mutual funds in 1 country hold shares of UroGen Pharma Ltd. worth $211 million, about 12.0% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 68 funds added shares and 24 sold; on balance they bought $26 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.